Q2 2025 Morepen Laboratories Ltd Earnings Call Transcript
Key Points
- Morepen Laboratories Ltd (BOM:500288) successfully raised INR 200 crore through a QIP, attracting global investors like Bank of America and Morgan Stanley.
- The company reported a 64% increase in profit after tax, demonstrating strong financial performance.
- Morepen Laboratories Ltd is expanding its medical devices segment, which now contributes 30% of the business, with plans to increase this to 40% in the next five years.
- The company has achieved a significant increase in export revenues, with a 20% growth in exports during the first half of the fiscal year.
- Morepen Laboratories Ltd has received product registration with USFDA and Health Canada, enabling it to start exporting medical devices to the US and Canada.
- The company experienced a decline in domestic API sales, particularly in low-yielding markets like India, Bangladesh, and Pakistan.
- There were capacity constraints in the production of medical devices, affecting the growth in this segment.
- The company's EBITDA margin, although improved, is still below the industry standard, with a target to reach 15% in the next three years.
- Morepen Laboratories Ltd faces challenges in the South American market due to competitive tender pricing.
- The company is still in the process of expanding its finished dosage facility, which has faced delays due to regulatory approvals.
Ladies and gentlemen, good day. And welcome to Marin Laboratories Limited Q2 FY25 earnings conference call hosted by Motalal Oswal Financial Services.
As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call? Please signal an operator by pressing the star then zero on your touchtone phone.
Please note that this conference is being recorded.
I now hand the conference over to Mr Trushal Madhuran from Motalal Oswal Financial Services. Thank you and over to you, sir.
Thanks Steve very good afternoon and I welcome you all for Q2 FY 25 earnings call of modern laboratories. From the management side, we have Mr Sushil Suri, Chairman and managing director, Mr Ajay Kumar Sharma, Chief Financial Officer, Mr Vipul Kumar. She was our company secretary and compliance officer and Mr Nishan Jay do Vice President, corporate finance
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
